Ground-breaking HF trial with evidence for SGLT2i at EF>40%
This video was recorded during the digital ESC Congress 2021.
Professor Frank Ruschitzka, MD, is Chairman of the University Heart Center and the Department of Cardiology at the University Hospital in Zürich, Switzerland.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: